Summary of findings: Molecular‐targeted therapy plus chemotherapy vs chemotherapy alone
Severe adverse event (grade ≥ 3 ) Duration of · people with advanced gastric cancer
Summary of findings: Molecular‐targeted therapy plus chemotherapy probably leads to higher severe adverse event (grade ≥ 3 ) Duration of compared with chemotherapy alone (moderate certainty).
1 finding from 1 review
- Molecular‐targeted first‐line therapy for advanced gastric cancer 2016 · Cochrane Headline outcomes onlyOR 1.19 [1.03, 1.37]8 studies · 3800 participantsModerate